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7 APPENDIX  
7.1  RAT DIETS 
7.1.1 Semi-Synthetic and Experimental Rat Diets 
 
Ingredients      g/Kg 
Semi-synthetic Aspirin  Quercetin 
chow 
Vitamin mixture  20    20   20 
Mineral mixture  40     40   40 
 
DL-methionine   2    2   2 
 
Cellulose   100    100   100 
Casein    200     200   200 
Starch    260     259.5   258.75 
Sucrose    298    298   298 
Corn oil   80    80   80 
Drug       0.5   1.25 
 









7.1.2  Components of the Mineral Mix 
 
Ingredients      g/Kg 
Calcium Hydrogen Orthophosphate   322.8 
(CaHPO4)       
Di-Sodium Hydrogen Orthophosphate   185 
(Na2HPO4) 
Calcium Carbonate     205 
(CaCO3) 
Potassium Chloride     175.5 
(KCl) 
Magnesium Sulphate (dried)    100 
(MgSO4) 
 
Trace Element Pre Mix (added to Mineral Mix) 
Ingredients      g/Kg 
Zinc Carbonate (ZnCO3)    2.5 
Ferrous Sulphate (FeSO4)    3.6 
Cupric Sulphate (CuSO4)    0.575 
Potassium Iodate (KIO3)    0.025 






7.1.3  Components of the Vitamin Mix 
 
Ingredients    g/Kg 
Nicotinic Acid    3 
B12 in Mannitol   2.5 
D-Pantothenic Acid   2 
Thiamine Hydrochloride (B1)  0.5 
Riboflavin (B2)    0.5 
Pyridoxine    0.5 
Folic Acid    0.5 
D-Biotin    0.05 
Vitamin K1    0.1 
Rovi Mix E50     7.5 
Rovi Mix A500    1.25 
Rovi Mix D3500   0.75 
Choline Bitartrate   90 
Starch     890.85 
 
 
